Veracyte (VCYT) reported $517M in revenue for fiscal 2025, +16.0% year on year. That ranks #2188 by revenue among 2853 SEC filers and #211 in Healthcare. Net income was $66.4M, a net margin of 12.8%. Revenue has grown 25.9% a year on average since 2016 ($65.1M then). The fiscal 2025 balance sheet shows $1.4B in total assets, $363M in cash and $0 in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $517M | +16.0% | FY20252025-12-31 |
| Gross profitGrossProfit | $363M | +21.6% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $57.8M | +257.9% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $66.4M | +175.5% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $136M | +81.5% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $9.7M | −14.3% | FY20252025-12-31 |
| Total assetsAssets | $1.4B | +8.2% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $1.3B | +11.4% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $363M | +51.7% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $0 | −100.0% | FY20212021-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $139M | $28.7M | Open → |
| Q2 20262026-06-30 | $150M | $25.5M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Veracyte, Inc.
- Ticker
- VCYT
- Exchange
- Nasdaq
- SIC classification
- Services-Medical Laboratories (8071)
- Fiscal year end
- 12-31
- CIK
- 0001384101
Filings
- 10-QJul 31, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| HUTCHMED (China)HCM | $549M | $457M |
| AtricureATRC | $535M | −$11.4M |
| Mirum PharmaceuticalsMIRM | $521M | −$23.4M |
| VeracyteVCYT | $517M | $66.4M |
| InotivNOTVQ | $513M | −$68.6M |
| Adma BiologicsADMA | $510M | $147M |
| GlaukosGKOS | $507M | −$188M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Veracyte — Key figures |url=https://companiesranked.com/en/company/veracyte |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Veracyte — Key figures. CompaniesRanked. https://companiesranked.com/en/company/veracyteBibTeX
@misc{companiesranked-en-company-veracyte-2026,
author = {{CompaniesRanked}},
title = {{Veracyte — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/veracyte}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001384101-26-000010 · February 26, 2026
{{cite web |title=Veracyte — Key figures — 10-K (0001384101-26-000010) |url=https://www.sec.gov/Archives/edgar/data/1384101/000138410126000010/vcyt-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.